Skip to main content
Clinical Trials/NCT00517101
NCT00517101UnknownNot Applicable

Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy

Tel-Aviv Sourasky Medical Center0 sitesStarted: September 2007Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable

Study Overview

Brief Summary

A relationship between IBD and spondyloarthropathy is well recognized. ASCA ( anti saccharomyces cerevisiae antibodies)are considered to be a serological marker for Crohn's disease and have been studied in patients with spondyloarthropathy with conflicting results. More recently, new serological markers for IBD have been described. These markers are antibodies to certain defined glycans , and their use may permit an improved diagnosis of IBD.

The aim of our study is to investigate wether these new serological markers are present in the sera of patients with spondyloarthropathy.

Study Design

Study Type
Observational
Observational Model
Defined Population
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • diagnosis of psoriatic arthritis, ankylosing spondylitis, or undifferentiated spondyloarthropathy

Exclusion Criteria

  • diagnosed inflammatory bowel disease

Investigators

Sponsor Class
Other Gov

Similar Trials